Phaseline

Targets › CLN2

CLN2 (Tripeptidyl-peptidase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.

Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. (UniProt, O14773)

Open in Phaseline: the race on CLN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tern TherapeuticsTTX-381
AAV9-mediated hCLN2 gene therapy
CLN2Phase 1Neuronal Ceroid Lipofuscinosis Type 2Dec 2026

Conditions

Neuronal Ceroid Lipofuscinosis Type 2 (1)

Modalities

other (1)

Companies

Tern Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.